Oral paclitaxel and HM30181A demonstrate clinical activity in metastatic breast cancer (MBC) patients

M. DAI, Tsu-Yi Chao, T. Chao, C. Chiu, Y. Lu, H. Shiah, Y. Wu, G. Gerald Fetterly, N. Hung, D.L. Cutler, R. Kwan, D. Douglas Kramer, W. Chan, T. Hung

研究成果: 雜誌貢獻文章


Intravenous (IV) paclitaxel is approved for the treatment of numerous cancers including MBC. Oraxol (Athenex, USA), is an oral formulation of paclitaxel in combination with a novel, orally active, potent and specific inhibitor of P-gp (HM30181A). Oraxol is expected to be less toxic with comparable efficacy to its iv counterpart. We report the interim results of an ongoing study of Oraxol in MBC patients.
期刊Annals of Oncology
出版狀態已發佈 - 十月 21 2018